PC
TEVA icon

PointState Capital’s Teva Pharmaceuticals TEVA Stock Holding History

PointState Capital’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1,973,782
Closed -$59.5M – 67
2026
Q1 		$59.5M Sell
1,973,782
-1,820,204
-48% -$58.6M 0.75% 26
2025
Q4 		$118M Sell
3,793,986
-16,918,412
-82% -$417M 1.74% 27
2025
Q3 		$418M Hold
20,712,398
– – 6.25% 2
2025
Q2 		$347M Buy
20,712,398
+5,580,910
+37% +$90.1M 5.29% 2
2025
Q1 		$233M Buy
15,131,488
+1,605,013
+12% +$28.7M 3.37% 6
2024
Q4 		$298M Buy
13,526,475
+3,768,131
+39% +$68.6M 5.43% 3
2024
Q3 		$176M Buy
9,758,344
+611,621
+7% +$10.7M 3.19% 8
2024
Q2 		$149M Buy
9,146,723
+4,041,754
+79% +$62.3M 3.23% 9
2024
Q1 		$72M Buy
+5,104,969
New +$64.3M 1.23% 21
2018
Q3 		– Sell
-6,654,040
Closed -$162M – 184
2018
Q2 		$162M Buy
+6,654,040
New +$136M 1.83% 17
2016
Q4 		– Sell
-9,033,053
Closed -$416M – 162
2016
Q3 		$416M Sell
9,033,053
-5,918,607
-40% -$309M 4.29% 2
2016
Q2 		$751M Buy
14,951,660
+6,679,082
+81% +$356M 15.47% 1
2016
Q1 		$443M Sell
8,272,578
-816,931
-9% -$47.9M 11.93% 1
2015
Q4 		$597M Buy
9,089,509
+4,137,079
+84% +$256M 15.16% 1
2015
Q3 		$280M Sell
4,952,430
-4,753,161
-49% -$308M 7.82% 3
2015
Q2 		$574M Sell
9,705,591
-604,374
-6% -$37.3M 6.71% 2
2015
Q1 		$642M Buy
10,309,965
+2,216,808
+27% +$129M 8.69% 1
2014
Q4 		$465M Sell
8,093,157
-2,297,024
-22% -$128M 7.93% 1
2014
Q3 		$558M Sell
10,390,181
-2,084,924
-17% -$110M 10.13% 1
2014
Q2 		$654M Sell
12,475,105
-261,395
-2% -$13.4M 8.22% 3
2014
Q1 		$673M Buy
12,736,500
+3,291,100
+35% +$152M 10.71% 2
2013
Q4 		$379M Buy
+9,445,400
New +$372M 4.78% 3

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

PointState Capital's TEVA Position: Q2 2026 in Review

PointState Capital sold out of Teva Pharmaceuticals (TEVA) in Q2 2026, closing a stake of 1,973,782 shares — an estimated $59.5M sold.

PointState Capital first reported a position in TEVA in Q4 2013 and held it in 22 quarters. The position peaked at $751M in Q2 2016. 672 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

  • PointState Capital reported no remaining Teva Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • PointState Capital sold 1,973,782 Teva Pharmaceuticals shares in Q2 2026, an estimated $59.5M.
  • PointState Capital first reported a position in Teva Pharmaceuticals in Q4 2013 and held it in 22 quarters.
  • PointState Capital's Teva Pharmaceuticals position peaked at $751M in Q2 2016.
  • 672 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on PointState Capital's 13F filing for Q2 2026, filed 14 Aug 2026.